Endo's New Spatial Computing Injection Simulator for Peyronie's Disease Creates Immersive Learning Environment for Urology Specialists

Cision Canada

24-04-2025

Endo Will Launch the Simulator at the American Urological Association (AUA) Annual Meeting
MALVERN, Pa., April 24, 2025 /CNW/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of a Spatial Computing Injection Simulator for Peyronie's disease. The simulator allows urology specialists to interact simultaneously with both physical and digital objects—blending a physical penile model and digital content via an Apple Vision Pro app—to help refine their injection technique. Endo will launch the experience at the American Urological Association (AUA) Annual Meeting, the largest gathering of urologists in the world, which takes place April 26-29, 2025.
"We know that healthcare providers value hands-on approaches to learning, and technology like the Spatial Computing Injection Simulator can make a huge difference for the surgeons and advanced practice providers who treat Peyronie's disease," said Justin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. "With a mix of tactical practice, videos of real procedures, and the inclusion of practical information, the simulator is an example of innovation that can enhance patient care."
The Spatial Computing Injection Simulator was designed to help urology specialists refine their injection technique in the penis for the administration of XIAFLEX ® (collagenase clostridium histolyticum), the only FDA-approved nonsurgical treatment for Peyronie's disease.
Do not receive XIAFLEX ® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX ®, or to any other collagenase product.
During the immersive, 20-minute Spatial Computing Injection Simulator experience, urology specialists receive hands-on practice on product reconstitution and injection angles, watch procedures in action, practice their injection technique on the penile model, and acquire information on the post-injection process. This can help them refine their technique for the treatment of real patients with XIAFLEX, which represents an important treatment option to help appropriate patients. 1
This is the second time Endo has used the power of spatial computing (also called "mixed reality") to create an immersive learning environment for healthcare providers. The first was developed for hand specialists who treat patients with Dupuytren's contracture.
Endo worked with technology agency Lucid Dream to create the Apple Vision Pro app and spatial computing experience.
About Peyronie's Disease
Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy. 2 It is estimated that PD can affect as many as 1 in 10 men in the U.S., 3 but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help. 4
IMPORTANT SAFETY INFORMATION
Do not receive XIAFLEX if:
the Peyronie's plaque to be treated involves the "tube" that your urine passes through (urethra).
you are allergic to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.
XIAFLEX can cause serious side effects, including:
1. Penile fracture (corporal rupture) or other serious injury to the penis. Receiving an injection of XIAFLEX may cause damage to the tubes in your penis called the corpora. After treatment with XIAFLEX, one of these tubes may break during an erection. This is called a corporal rupture or penile fracture. This could require surgery to fix the damaged area. Damage to your penis might not get better after a corporal rupture.
After treatment with XIAFLEX, blood vessels in your penis may also break, causing blood to collect under the skin (hematoma). This could require a procedure to drain the blood from under the skin. If a hematoma appears, skin and soft tissue necrosis (death of skin cells) may develop in that area, which could require surgery.
Symptoms of corporal rupture or other serious injury to your penis may include:
a popping sound or sensation in an erect penis
sudden loss of the ability to maintain an erection
pain in your penis
purple bruising and swelling of your penis
difficulty urinating or blood in the urine
Call your healthcare provider right away if you have any of the symptoms of corporal rupture or serious injury to the penis listed above.
Do not have sex or any other sexual activity between the first and second injections of a treatment cycle.
Do not have sex or have any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with XIAFLEX and after any pain and swelling has gone away.
XIAFLEX for the treatment of Peyronie's disease is only available through a restricted program called the XIAFLEX Risk Evaluation and Mitigation Strategy (REMS) Program.
2. Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX, because it contains foreign proteins.
Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
3. Back pain reactions. After receiving an injection of XIAFLEX for Peyronie's disease, you may suddenly feel back pain, including severe lower back pain moving to your legs, feet, chest and arms. The back pain may also include spasms and make it hard to walk. These symptoms usually go away in 15 minutes or less, but may last longer.
Tell your healthcare provider right away if you have sudden back pain, chest pain, or hard time walking after an injection.
4. Fainting. Fainting (passing out) or near fainting can happen in men who receive XIAFLEX, especially if they have severe penile pain.
If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away.
Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, have a bleeding problem, received XIAFLEX for another condition, or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.
What should I avoid while receiving XIAFLEX?
Avoid situations that may cause you to strain your stomach (abdominal) muscles, such as straining during bowel movements.
Do not use a vacuum erection device during your treatment with XIAFLEX.
XIAFLEX can cause serious side effects, including increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.
The most common side effects with XIAFLEX for the treatment of Peyronie's disease include:
a small collection of blood under the skin at the injection site (hematoma)
swelling at the injection site or along your penis
pain or tenderness at the injection site, along your penis and above your penis
penis bruising
itching of your penis or scrotum (genitals)
painful erection
erection problems (erectile dysfunction)
changes in the color of the skin of your penis
blisters at the injection site
pain with sex
a lump at the injection site (nodule)
Tell your healthcare provider if you have any side effect that bothers you or does not go away.
These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.
WHAT IS XIAFLEX?
XIAFLEX is a prescription medicine used to treat adult men with Peyronie's disease who have a "plaque" that can be felt and a curve in their penis greater than 30 degrees when treatment is started.
It is not known if XIAFLEX is safe and effective in children under the age of 18.
Rx Only
Click for full Prescribing Information, including BOXED WARNING and Medication Guide.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Mattice and any statements relating to the injection simulator, product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-K and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.
XIAFLEX ® [Prescribing Information]. Rochester, MI: Endo USA, Inc.
Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.
Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
DiBenedetti DB, Nguyen D, Zografoset L, et al. Adv Urol. 2011:282503.